Danuglipron reddit: Why Pfizer Dropped the Pill

Danuglipron Reddit discussion now reads like a promising trial story with a hard stop: Pfizer’s oral GLP-1 lowered weight and blood sugar in randomized human studies, but high gastrointestinal dropout rates and one potential drug-induced liver injury ended development. The cancellation killed this molecule, not the whole idea of oral GLP-1 drugs.

Why was Reddit excited about danuglipron?

Danuglipron drew attention because Pfizer was testing a true small-molecule pill that activated the GLP-1 receptor without an injection or the fasting rules attached to oral peptide formulations. Early r/science discussion centered on efficacy, convenience, cost, insurance access, and whether a pill could broaden GLP-1 use. Those hopes were reasonable, but they were forecasts, not danuglipron results.

Danuglipron was not a peptide squeezed into tablet form. The danuglipron evidence profile identifies PF-06882961 as a synthetic, non-peptide small molecule aimed at the same receptor used by familiar GLP-1 medicines. Different key, same lock. Our guide to how GLP-1 drugs work explains that shared target.

Did danuglipron actually work?

Danuglipron showed real efficacy in human randomized controlled trials, so “Pfizer dropped it because it did nothing” is wrong. In a 411-person type 2 diabetes trial, all tested doses lowered HbA1c and fasting glucose versus placebo at 16 weeks; the two highest doses also reduced body weight (Saxena et al., 2023). That is Human RCT evidence, not an animal result wearing a lab coat.

The obesity trial also met its main endpoint. Pfizer reported placebo-adjusted mean weight reductions of 5% to 9.5% at 26 weeks and 8% to 13% at 32 weeks. The same report recorded discontinuation above 50% across doses, versus about 40% with placebo (Pfizer’s Phase 2b results). A compound can work and still be a poor medicine to advance.

Why was danuglipron discontinued?

Danuglipron was discontinued in two steps, a timeline that quick summaries often flatten. Pfizer first decided in December 2023 not to move the twice-daily formulation into Phase 3 because gastrointestinal adverse events and dropouts were too high. Pfizer kept developing a once-daily formulation, then ended the entire molecule on April 14, 2025 after one participant had potential drug-induced liver injury.

Pfizer described that participant as asymptomatic and said the injury resolved after danuglipron stopped. The company also said liver-enzyme elevation rates across more than 1,400 participants were in line with approved drugs in the class. After reviewing the full record and regulator input, Pfizer halted development (Pfizer’s discontinuation update). “Danuglipron discontinued” therefore means a program-level benefit-risk decision, not proof that every participant suffered liver damage.

Did the liver signal prove oral GLP-1 pills are unsafe?

Danuglipron’s liver case did not prove that oral GLP-1 pills are unsafe as a class. The honest evidence tier is narrower: one potential injury ended this molecule after earlier tolerability trouble. Route, receptor, and molecule are three different questions; swallowing a drug does not make every compound with the same target share an identical safety profile.

This is where the Reddit post-mortem is most useful. Community disappointment correctly tracks the loss of a convenient candidate. The overreach comes when one safety decision becomes a class verdict. Drug development is less like picking a winning receptor and more like sending many keys through the same lock test. Some turn cleanly. Some jam.

Danuglipron vs orforglipron: what changed by 2026?

Danuglipron failed as a product candidate, while orforglipron proved that a non-peptide oral GLP-1 could clear the regulatory bar. The FDA approved orforglipron as Foundayo on April 1, 2026 for chronic weight management in eligible adults (FDA approval announcement). That approval is the cleanest answer to claims that Pfizer’s setback doomed the format.

The comparison does not rehabilitate danuglipron. Pfizer’s candidate still combined efficacy with high dropout rates and a potential liver injury. Orforglipron’s approval shows only that another molecule, tested in its own program, produced a benefit-risk record the FDA accepted. Same broad concept, different evidence package. Molecules do not receive group projects.

Where is Reddit right — and where is it off?

Reddit is right that the Pfizer oral GLP-1 produced meaningful human trial signals, that nausea and vomiting were not minor footnotes, and that losing a needle-free candidate was disappointing. GLP-1 community discussion also correctly separated excitement about oral options from concern about danuglipron’s tolerability. Those are observations worth carrying into the evidence.

Reddit is off when trial efficacy becomes proof of a usable medicine, one potential liver injury becomes a universal class effect, or an online listing is treated as the Pfizer trial drug. Danuglipron never became an FDA-approved product, and Pfizer ended the program. No testimonial, vendor label, or “research” disclaimer changes that status.

What is the honest bottom line?

Danuglipron reddit discussion preserves both halves of the story: the compound worked on weight and glucose outcomes in human randomized trials, and Pfizer still had sound reasons to stop. The useful verdict is Human RCT efficacy, failed development program. That is more precise than calling the drug either a scam or a suppressed success.

Danuglipron’s failure also says less about oral GLP-1s than it did in 2025. Orforglipron’s 2026 approval settled the platform question while leaving the molecule-specific safety lesson intact. The oral idea survived. Danuglipron did not.